down arrow

aTyr Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0021202025
USD
0.83
0.12 (17.35%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.750.86

52 Week

0.647.29
Valuation
Technical
Day's Volume

CASH

3.23 M

Shareholding (Jun 2025)

FII

5.68%

Held by 39 FIIs

DII

47.43%

Held by 54 DIIs

Promoter

0.45%

How big is aTyr Pharma, Inc.?

22-Jun-2025

As of Jun 18, aTyr Pharma, Inc. has a market capitalization of 457.48 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -63.42 million over the latest four quarters. The company reported shareholder's funds of 70.02 million and total assets of 98.05 million as of Dec 24.

Market Cap: As of Jun 18, aTyr Pharma, Inc. has a market capitalization of 457.48 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, aTyr Pharma, Inc. reported net sales of 0.00 million and a net profit of -63.42 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 70.02 million and total assets of 98.05 million.

Read More

What does aTyr Pharma, Inc. do?

22-Jun-2025

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company focused on developing medicines for severe, rare diseases. It has a market cap of $457.48 million and reported a quarterly net loss of $15 million as of March 2025.

Overview:<BR>aTyr Pharma, Inc. is a clinical-stage biotherapeutics company engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: Not available<BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 457.48 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.00<BR>Return on Equity: -84.50%<BR>Price to Book: 6.10<BR><BR>Contact Details:<BR>Address: 3545 John Hopkins Ct Ste 250, SAN DIEGO CA: 92121-1115<BR>Tel: 1 858 7318389<BR>Fax: 1 858 7318394<BR>Website: https://www.atyrpharma.com/

Read More

Who are in the management team of aTyr Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of aTyr Pharma, Inc. includes John Clarke (Independent Chairman), Sanjay Shukla (President and CEO), and several independent directors: Timothy Coughlin, Jane Gross, Jeffrey Hatfield, Svetlana Lucas, and Paul Schimmel. They oversee the company's strategic direction and operations.

As of March 2022, the management team of aTyr Pharma, Inc. includes the following individuals:<BR><BR>- Mr. John Clarke, Independent Chairman of the Board<BR>- Dr. Sanjay Shukla, President, Chief Executive Officer, and Director<BR>- Mr. Timothy Coughlin, Independent Director<BR>- Dr. Jane Gross, Independent Director<BR>- Mr. Jeffrey Hatfield, Independent Director<BR>- Ms. Svetlana Lucas, Independent Director<BR>- Dr. Paul Schimmel, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is aTyr Pharma, Inc. overvalued or undervalued?

25-Jun-2025

As of March 14, 2024, aTyr Pharma, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to negative financial metrics, including a P/E ratio of NA, a Price to Book Value of 6.38, an EV to EBITDA of -6.14, and a troubling ROE of -84.50%, indicating it underperforms compared to peers like Chimerix and DiaMedica.

As of 14 March 2024, the valuation grade for aTyr Pharma, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a P/E ratio of NA due to losses, a Price to Book Value of 6.38, and an EV to EBITDA of -6.14. Additionally, the ROE stands at a concerning -84.50%, reflecting the company's struggles to generate returns for shareholders.<BR><BR>In comparison with peers, aTyr Pharma's valuation metrics are notably weaker, with Chimerix, Inc. also categorized as does not qualify and showing a P/E of -8.6897, while DiaMedica Therapeutics, Inc. has a P/E of -5.6701. The overall peer comparison suggests that aTyr Pharma is not only underperforming against its immediate competitors but also lacks the financial stability to justify its current price. Despite a strong year-to-date return of 37.57%, the valuation metrics indicate that the stock is overvalued in the current market context.

Read More

Is aTyr Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, aTyr Pharma, Inc. shows a bullish trend overall, despite mixed signals from indicators like MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -70.99%.

As of 12 September 2025, the technical trend for aTyr Pharma, Inc. has changed from mildly bullish to bullish. However, the overall stance remains mixed due to conflicting indicators. The MACD shows a mildly bearish signal on the weekly timeframe but is bullish on the monthly. The RSI is bullish on the weekly but has no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, while the Bollinger Bands and Dow Theory are bearish on both weekly and monthly timeframes. <BR><BR>In terms of performance, aTyr Pharma has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -70.99% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish but with weak strength due to the mixed signals from various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 535 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.06

stock-summary
Return on Equity

-89.04%

stock-summary
Price to Book

7.15

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-85.5%
0%
-85.5%
6 Months
-84.64%
0%
-84.64%
1 Year
-75.14%
0%
-75.14%
2 Years
-34.82%
0%
-34.82%
3 Years
-64.16%
0%
-64.16%
4 Years
-89.39%
0%
-89.39%
5 Years
-81.77%
0%
-81.77%

aTyr Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is aTyr Pharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for aTyr Pharma, Inc. has changed from mildly bullish to bullish. However, the overall stance remains mixed due to conflicting indicators. The MACD shows a mildly bearish signal on the weekly timeframe but is bullish on the monthly. The RSI is bullish on the weekly but has no signal on the monthly. Moving averages indicate a mildly bullish trend on the daily, while the Bollinger Bands and Dow Theory are bearish on both weekly and monthly timeframes. In terms of performance, aTyr Pharma has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -70.99% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish but with weak strength due to the mixed signals from various indicators....

Read More
aTyr Pharma Hits 52-Week Low at $0.97 Amidst Significant Decline

aTyr Pharma Hits 52-Week Low at $0.97 Amidst Significant Decline

aTyr Pharma, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, faces financial challenges, including a high price-to-book ratio and negative return on equity, while maintaining a volatile market presence.

Read More
aTyr Pharma Hits 52-Week Low at $1.00 Amidst Market Struggles

aTyr Pharma Hits 52-Week Low at $1.00 Amidst Market Struggles

aTyr Pharma, Inc. has reached a new 52-week low of USD 1.00, reflecting a 47.41% decline over the past year. The company, with a market capitalization of USD 535 million, faces financial challenges, including a high price-to-book ratio and negative return on equity, amid ongoing industry volatility.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-219.14%
EBIT to Interest (avg)
-47.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
87.81%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.38
EV to EBIT
-6.02
EV to EBITDA
-6.14
EV to Capital Employed
-403.78
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-84.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 18 Schemes (46.44%)

Foreign Institutions

Held by 39 Foreign Institutions (5.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -30.87% vs 0.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.90",
          "val2": "-15.40",
          "chgp": "-29.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.50",
          "val2": "-14.90",
          "chgp": "-30.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -50.00% vs -96.15% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -26.98% vs -11.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.40",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-66.40",
          "val2": "-52.20",
          "chgp": "-27.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-64.00",
          "val2": "-50.40",
          "chgp": "-26.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-288,995.70%",
          "val2": "-155,577.90%",
          "chgp": "-13,341.78%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.90
-15.40
-29.22%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-19.50
-14.90
-30.87%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -30.87% vs 0.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.40
-50.00%
Operating Profit (PBDIT) excl Other Income
-66.40
-52.20
-27.20%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-64.00
-50.40
-26.98%
Operating Profit Margin (Excl OI)
-288,995.70%
-155,577.90%
-13,341.78%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -50.00% vs -96.15% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -26.98% vs -11.26% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About aTyr Pharma, Inc. stock-summary
stock-summary
aTyr Pharma, Inc.
Pharmaceuticals & Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Company Coordinates stock-summary
Company Details
3545 John Hopkins Ct Ste 250 , SAN DIEGO CA : 92121-1115
stock-summary
Tel: 1 858 7318389
stock-summary
https://www.atyrpharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."